-

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

Company Announces Participation in BTIG Virtual Biotechnology Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.

In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences:

  • BTIG Virtual Biotechnology Conference 2023 – Fireside chat presentation will be held virtually on Monday, August 7th, 2023 at 3:00 PM ET.

A replay of the fireside chat from the BTIG conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations following the event.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The Company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.

Contacts

Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

Industry:

Agenus

NASDAQ:AGEN
Release Versions
English

Contacts

Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com

Media Contact
781-674-4784
communications@agenusbio.com

More News From Agenus

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab (BOT), alone or in combination with balstilimab (BAL), have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago, Illinois. The accepted abstracts reflect continued progress of Agenus’ botensilimab and balstilimab immunotherapy program ac...

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

LEXINGTON, Mass. & MARLOW, England--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus’ global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Ef...

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, MiNK’s allo-iNKT cell therapy, ramucirumab and paclitaxel in patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The data are being presented at the American Association for Cancer...
Back to Newsroom